Search for Stocks /

Anupam Rasayan Q3 FY26: 31% Revenue Growth, 74% PAT Jump, 85x P/E – Global Chemical Powerhouse or Expensive Experiment?


1. At a Glance – The Chemical That Refuses to Behave

Anupam Rasayan India Ltd is currently priced at ₹1,285, commanding a market cap of ₹14,643 crore and trading at a royal P/E of 85.1. Yes, eighty-five. The stock has doubled over the last year (100% return) and delivered 3.06% in 3 months while investors argue whether it’s a genius global specialty play or an overconfident chemistry lab experiment.

Q3 FY26 numbers?

Revenue: ₹512 crore (+31% YoY)
PAT: ₹61 crore (+12% YoY)
OPM: 25%
ROCE: 7.33%
ROE: 3.32%
Debt: ₹1,223 crore
Promoter Holding: 59.07% (with 16% pledged)

On paper, growth looks shiny. On valuation, it looks expensive. On balance sheet, it looks stretched. On ambition? It looks global.

This is not a simple chemical manufacturer. This is a fluorination-heavy, US-acquisition-hunting, ECB-borrowing, pipeline-touting specialty chemical machine trying to go global.

The question is — are you paying for tomorrow’s potential or yesterday’s story?

Let’s dissect.


2. Introduction – From Surat to the United States

Anupam Rasayan started as a specialty chemical manufacturer in Gujarat. Simple enough.

But today?

It talks about:

  • US acquisitions
  • Fluorination platforms
  • Pharma KSM import substitution
  • Advanced materials
  • Electronics chemicals
  • EV ecosystem
  • Green energy investments

This is no longer just an agro intermediate supplier.

The company operates 6 manufacturing facilities in Gujarat, capacity of ~27,000 MT, utilization at 70–75%. It serves 75 customers including 31 MNCs, with top 10 contributing 77% of revenue.

Yes. Customer concentration is real.

But entry barriers are also real — management claims 12–24 months to acquire a client. That’s sticky.

Now, Q3 FY26 shows improvement after industry normalization in agro. Pharma and Performance Materials are growing faster than legacy agro.

But here’s the tension:

  • Growth is back
  • Working capital is heavy
  • Debt has increased
  • ROE is low
  • Valuation is premium

Are we looking at a compounding machine in early stage — or an over-engineered balance sheet?

Keep reading.


3.

Read Full 16 Point breakdown. Continue reading →
Members get full access to every article.
Become a member
Already a member? Log in
Read Full 16 Point breakdown. Continue reading →